Home › Trial NCT06328738
ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
- Trial IDNCT06328738
- StatusActive Not Recruiting
- PhasePhase 1
- Study typeInterventional
- SponsorEnliven Therapeutics
- Enrollment275
- Start date2024-05-30
- ConditionsHER2-positive Breast Cancer · HER2-positive Gastric Cancer · HER2 Positive Solid Tumors · HER2 Amplification · Colorectal Cancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.